Aerocrine’s NIOX MINO device for measuring FeNO receives approval by Health Canada.
Medtech company Aerocrine AB announced in mid-April that Health Canada’s Therapeutic Products Directorate has authorized Aerocrine’s latest NIOX MINO for use in identifying allergic airway inflammation.
According to Aerocrine, NIOX MINO measures fractional exhaled nitric oxide (FeNO), which is a direct, non-invasive way to assess the allergic airway inflammation which characterizes many adults and children with asthma. Physicians use FeNO to identify allergic airway inflammation in patients with suspected asthma, to help predict patient response to corticosteroid therapy, as well as to help assess adherence to corticosteroid therapy.
“The approval in Canada is another step forward for Aerocrine and means that Aerocrine’s innovative technology will now be available throughout North America. We are actively evaluating our distribution needs in Canada in light of this important approval,” said Ken Marshall, President Aerocrine, Inc. in a press release.